share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/08/16 14:08

Moomoo AI 已提取核心信息

Transcode Therapeutics received two deficiency notices from Nasdaq on August 13 and 15, 2024. The first notice cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 through August 12. Due to two previous reverse stock splits, the company is not eligible for the standard 180-day compliance period.The second notice indicated non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported stockholders' equity of $1.32 million in Q2 2024. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma stockholders' equity to $3.7 million, there is no assurance Nasdaq will consider this adjustment.Transcode plans to request a hearing before the Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action. The panel will consider both deficiencies during the hearing. The company must submit its hearing request regarding the stockholders' equity requirement by August 22, 2024, if it regains compliance with the minimum bid price requirement before then.
Transcode Therapeutics received two deficiency notices from Nasdaq on August 13 and 15, 2024. The first notice cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 through August 12. Due to two previous reverse stock splits, the company is not eligible for the standard 180-day compliance period.The second notice indicated non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported stockholders' equity of $1.32 million in Q2 2024. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma stockholders' equity to $3.7 million, there is no assurance Nasdaq will consider this adjustment.Transcode plans to request a hearing before the Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action. The panel will consider both deficiencies during the hearing. The company must submit its hearing request regarding the stockholders' equity requirement by August 22, 2024, if it regains compliance with the minimum bid price requirement before then.
Transcode Therapeutics于2024年8月13日和15日收到了纳斯达克发出的两份缺陷通知。第一份通知指出，从7月1日到8月12日，该公司未能保持连续30个交易日的最低1.00美元买盘价要求。由于之前进行了两次拆股并股，该公司不符合标准的180天合规期。第二份通知显示，该公司未能满足最低股东权益要求250万美元，因为在2024年第二季度公司报告的股东权益为132万美元。尽管2024年7月的股权发行增加了约240万美元的净收益，使得形式上股东权益达到370万美元，但纳斯达克不一定会考虑此调整。Transcode计划向纳斯达克听证委员会请求一次听证会，这将自动暂停任何暂停或退市的行动。委员会将在听证会上考虑这两个缺陷。公司必须在2024年8月22日之前提交关于股东权益要求的听证请求，前提是公司在此之前已恢复对最低买盘价要求的合规。
Transcode Therapeutics于2024年8月13日和15日收到了纳斯达克发出的两份缺陷通知。第一份通知指出，从7月1日到8月12日，该公司未能保持连续30个交易日的最低1.00美元买盘价要求。由于之前进行了两次拆股并股，该公司不符合标准的180天合规期。第二份通知显示，该公司未能满足最低股东权益要求250万美元，因为在2024年第二季度公司报告的股东权益为132万美元。尽管2024年7月的股权发行增加了约240万美元的净收益，使得形式上股东权益达到370万美元，但纳斯达克不一定会考虑此调整。Transcode计划向纳斯达克听证委员会请求一次听证会，这将自动暂停任何暂停或退市的行动。委员会将在听证会上考虑这两个缺陷。公司必须在2024年8月22日之前提交关于股东权益要求的听证请求，前提是公司在此之前已恢复对最低买盘价要求的合规。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股集体大涨！2025年中国资产前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 $阿里巴巴 (BABA.US)$ 、 $京东 (JD.US)$ 、 $富途控股 (FUTU.US)$ 等中概股价格飙升，市场情绪火热。 🎙️讨论： Deepseek 展开
    中国股票的疯狂反弹暂停？华尔街仍在大举押注热门股票